A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots

Junyoung Seo, Taslim A. Al-Hilal, Jun Goo Jee, Yong Lim Kim, Ha Jeong Kim, Byung Heon Lee, Soyoun Kim, In-San Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting hemostatic clots. Here, we generated a double chambered short-length ferritin (sFt) construct that has an N-terminal region fused to multivalent clot targeting peptides (CLT: CNAGESSKNC) and a C-terminal end fused to a microplasmin (μPn); CLT recognizes fibrin–fibronectin complexes in clots, μPn efficiently dissolves clots, and the assembly of double chambered sFt (CLT-sFt-μPn) into nanocage structure protects the activated-μPn from its circulating inhibitors. Importantly, activated CLT-sFt-μPn thrombolytic nanocage showed a prolonged circulatory life over activated-μPn and efficiently lysed the preexisting clots in both arterial and venous thromboses models. Thus, CLT-sFt-μPn thrombolytic nanocage platform represents the prototype of a targeted clot-busting agent with high efficacy and safety over existing thrombolytic therapies.

Original languageEnglish
Pages (from-to)633-642
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number3
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Ferritins
Peptides
Thrombosis
Blood
Thrombolytic Therapy
Hemostatics
Fibrinolysin
Fibrinolysis
Venous Thrombosis
microplasmin
Hemorrhage
Safety

Keywords

  • Clot targeting peptide
  • Ferritin
  • Microplasmin
  • Nanoparticle
  • Thrombolysis

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots. / Seo, Junyoung; Al-Hilal, Taslim A.; Jee, Jun Goo; Kim, Yong Lim; Kim, Ha Jeong; Lee, Byung Heon; Kim, Soyoun; Kim, In-San.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 3, 01.04.2018, p. 633-642.

Research output: Contribution to journalArticle

Seo, Junyoung ; Al-Hilal, Taslim A. ; Jee, Jun Goo ; Kim, Yong Lim ; Kim, Ha Jeong ; Lee, Byung Heon ; Kim, Soyoun ; Kim, In-San. / A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 3. pp. 633-642.
@article{9527611de88540ce8288636dfadf0c5a,
title = "A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots",
abstract = "The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting hemostatic clots. Here, we generated a double chambered short-length ferritin (sFt) construct that has an N-terminal region fused to multivalent clot targeting peptides (CLT: CNAGESSKNC) and a C-terminal end fused to a microplasmin (μPn); CLT recognizes fibrin–fibronectin complexes in clots, μPn efficiently dissolves clots, and the assembly of double chambered sFt (CLT-sFt-μPn) into nanocage structure protects the activated-μPn from its circulating inhibitors. Importantly, activated CLT-sFt-μPn thrombolytic nanocage showed a prolonged circulatory life over activated-μPn and efficiently lysed the preexisting clots in both arterial and venous thromboses models. Thus, CLT-sFt-μPn thrombolytic nanocage platform represents the prototype of a targeted clot-busting agent with high efficacy and safety over existing thrombolytic therapies.",
keywords = "Clot targeting peptide, Ferritin, Microplasmin, Nanoparticle, Thrombolysis",
author = "Junyoung Seo and Al-Hilal, {Taslim A.} and Jee, {Jun Goo} and Kim, {Yong Lim} and Kim, {Ha Jeong} and Lee, {Byung Heon} and Soyoun Kim and In-San Kim",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.nano.2017.12.022",
language = "English",
volume = "14",
pages = "633--642",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots

AU - Seo, Junyoung

AU - Al-Hilal, Taslim A.

AU - Jee, Jun Goo

AU - Kim, Yong Lim

AU - Kim, Ha Jeong

AU - Lee, Byung Heon

AU - Kim, Soyoun

AU - Kim, In-San

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting hemostatic clots. Here, we generated a double chambered short-length ferritin (sFt) construct that has an N-terminal region fused to multivalent clot targeting peptides (CLT: CNAGESSKNC) and a C-terminal end fused to a microplasmin (μPn); CLT recognizes fibrin–fibronectin complexes in clots, μPn efficiently dissolves clots, and the assembly of double chambered sFt (CLT-sFt-μPn) into nanocage structure protects the activated-μPn from its circulating inhibitors. Importantly, activated CLT-sFt-μPn thrombolytic nanocage showed a prolonged circulatory life over activated-μPn and efficiently lysed the preexisting clots in both arterial and venous thromboses models. Thus, CLT-sFt-μPn thrombolytic nanocage platform represents the prototype of a targeted clot-busting agent with high efficacy and safety over existing thrombolytic therapies.

AB - The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage that efficiently dissolves the clot without causing systemic fibrinolysis or disrupting hemostatic clots. Here, we generated a double chambered short-length ferritin (sFt) construct that has an N-terminal region fused to multivalent clot targeting peptides (CLT: CNAGESSKNC) and a C-terminal end fused to a microplasmin (μPn); CLT recognizes fibrin–fibronectin complexes in clots, μPn efficiently dissolves clots, and the assembly of double chambered sFt (CLT-sFt-μPn) into nanocage structure protects the activated-μPn from its circulating inhibitors. Importantly, activated CLT-sFt-μPn thrombolytic nanocage showed a prolonged circulatory life over activated-μPn and efficiently lysed the preexisting clots in both arterial and venous thromboses models. Thus, CLT-sFt-μPn thrombolytic nanocage platform represents the prototype of a targeted clot-busting agent with high efficacy and safety over existing thrombolytic therapies.

KW - Clot targeting peptide

KW - Ferritin

KW - Microplasmin

KW - Nanoparticle

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=85042187067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042187067&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2017.12.022

DO - 10.1016/j.nano.2017.12.022

M3 - Article

C2 - 29309907

AN - SCOPUS:85042187067

VL - 14

SP - 633

EP - 642

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 3

ER -